Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway
Sign Up to like & getrecommendations! Published in 2021 at "Cell Cycle"
DOI: 10.1080/15384101.2021.2009986
Abstract: ABSTRACT Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib, have been recommended as the first-line treatment reagent for advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms of drug resistance development… read more here.
Keywords: circ 0014235; yap; mir 146b; cell ... See more keywords